Olaparib

• 1st-line maintenance in BRCA-mutated advanced ovarian cancer after platinum response
• Platinum-sensitive relapsed ovarian cancer

Inhibits PARP1/2 → traps PARP on DNA → synthetic lethality in BRCA-deficient (HR-deficient) tumours.

• Requires BRCA1/2 or HRD testing
• MDS/AML risk with prolonged use
• Contraception mandatory + 6 months post

Standard

300 mg BD PO (2 × 150 mg tablets BD)

• AbsolutePregnancy — teratogenic in animals
• AbsoluteBreastfeeding + 1 month post
• CautionSevere hepatic/renal impairment

• Nausea, fatigue
• Anaemia, neutropenia, thrombocytopenia
• Pneumonitis (rare)
• MDS/AML (long-term)

• • Teratogenic — effective contraception during and for 6 months post treatment

• CYP3A4 strong inhibitors/inducers

  Avoid

  Dose adjustment required

• 💡 Full blood count monthly for 12 months, then quarterly
• 💡 Discuss fertility preservation before initiation